BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eloseily EM, Weiser P, Crayne CB, Haines H, Mannion ML, Stoll ML, Beukelman T, Atkinson TP, Cron RQ. Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis. Arthritis Rheumatol 2020;72:326-34. [PMID: 31513353 DOI: 10.1002/art.41103] [Cited by in Crossref: 78] [Cited by in F6Publishing: 69] [Article Influence: 26.0] [Reference Citation Analysis]
Number Citing Articles
1 CORIMUNO-19 Collaborative group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med 2021;9:295-304. [PMID: 33493450 DOI: 10.1016/S2213-2600(20)30556-7] [Cited by in Crossref: 45] [Cited by in F6Publishing: 31] [Article Influence: 45.0] [Reference Citation Analysis]
2 Cavalli G, Larcher A, Tomelleri A, Campochiaro C, Della-Torre E, De Luca G, Farina N, Boffini N, Ruggeri A, Poli A, Scarpellini P, Rovere-Querini P, Tresoldi M, Salonia A, Montorsi F, Landoni G, Castagna A, Ciceri F, Zangrillo A, Dagna L. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol 2021;3:e253-61. [PMID: 33655218 DOI: 10.1016/S2665-9913(21)00012-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 23.0] [Reference Citation Analysis]
3 Pasin L, Cavalli G, Navalesi P, Sella N, Landoni G, Yavorovskiy AG, Likhvantsev VV, Zangrillo A, Dagna L, Monti G. Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. Eur J Intern Med 2021;86:34-40. [PMID: 33581979 DOI: 10.1016/j.ejim.2021.01.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 14.0] [Reference Citation Analysis]
4 Schvartz A, Belot A, Kone-Paut I. Pediatric Inflammatory Multisystem Syndrome and Rheumatic Diseases During SARS-CoV-2 Pandemic. Front Pediatr 2020;8:605807. [PMID: 33344389 DOI: 10.3389/fped.2020.605807] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
5 Schulert GS, Cron RQ. The genetics of macrophage activation syndrome. Genes Immun 2020;21:169-81. [PMID: 32291394 DOI: 10.1038/s41435-020-0098-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
6 Henderson LA, Degar BA. HLH treatment: smarter, not harder. Blood 2022;139:3453-5. [PMID: 35708727 DOI: 10.1182/blood.2022016421] [Reference Citation Analysis]
7 Maniscalco V, Abu-Rumeileh S, Mastrolia MV, Marrani E, Maccora I, Pagnini I, Simonini G. The off-label use of anakinra in pediatric systemic autoinflammatory diseases. Ther Adv Musculoskelet Dis 2020;12:1759720X20959575. [PMID: 33149772 DOI: 10.1177/1759720X20959575] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 van de Veerdonk FL, Netea MG. Blocking IL-1 to prevent respiratory failure in COVID-19. Crit Care 2020;24:445. [PMID: 32682440 DOI: 10.1186/s13054-020-03166-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 15.5] [Reference Citation Analysis]
9 Teimury A, Mahmoodi Khaledi E. Current Options in the Treatment of COVID-19: A Review. Risk Manag Healthc Policy 2020;13:1999-2010. [PMID: 33116980 DOI: 10.2147/RMHP.S265030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Keenan C, Nichols KE, Albeituni S. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis. Front Immunol 2021;12:614704. [PMID: 33664745 DOI: 10.3389/fimmu.2021.614704] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Nasonov EL. IMMUNOPATHOLOGY AND IMMUNOPHARMACOTHERAPY OF CORONAVIRUS DISEASE 2019 (COVID-19): FOCUS ON INTERLEUKIN 6. Naučno-praktičeskaâ revmatologiâ 2020;58:245-61. [DOI: 10.14412/1995-4484-2020-245-261] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
12 Cavalli G, Dagna L. Anakinra in COVID-19-How to Interpret Elevations of Serum Liver Enzymes: Comment on the Article by Navarro-Millán et al. Arthritis Rheumatol 2021;73:549. [PMID: 32959495 DOI: 10.1002/art.41525] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Tang S, Li S, Zheng S, Ding Y, Zhu D, Sun C, Hu Y, Qiao J, Fang H. Understanding of cytokines and targeted therapy in macrophage activation syndrome. Semin Arthritis Rheum 2021;51:198-210. [PMID: 33385860 DOI: 10.1016/j.semarthrit.2020.12.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Appiah-Kubi A, Acharya S, Fein Levy C, Vlachos A, Ostovar G, Murphy K, Farrell A, Brower D, Lipton JM, Wolfe L, Aygun B. Varying presentations and favourable outcomes of COVID-19 infection in children and young adults with sickle cell disease: an additional case series with comparisons to published cases. Br J Haematol 2020;190:e221-4. [PMID: 32652551 DOI: 10.1111/bjh.17013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
15 Nasonov EL. Coronavirus disease 2019 (COVID-19) and autoimmunity. Naučno-praktičeskaâ revmatologiâ 2021;59:5-30. [DOI: 10.47360/1995-4484-2021-5-30] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 14.0] [Reference Citation Analysis]
16 Mendoza-Pinto C, García-Carrasco M, Realpozo PM, Méndez-Martínez S. [Therapeutic options for the management of severe Covid-19: A rheumatology perspective]. Reumatol Clin (Engl Ed) 2020. [PMID: 32426002 DOI: 10.1016/j.reuma.2020.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Kiselevskiy M, Shubina I, Chikileva I, Sitdikova S, Samoylenko I, Anisimova N, Kirgizov K, Suleimanova A, Gorbunova T, Varfolomeeva S. Immune Pathogenesis of COVID-19 Intoxication: Storm or Silence? Pharmaceuticals (Basel) 2020;13:E166. [PMID: 32722596 DOI: 10.3390/ph13080166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
18 Russo A, Morrone HL, Rotundo S, Trecarichi EM, Torti C. Cytokine Profile of Invasive Pulmonary Aspergillosis in Severe COVID-19 and Possible Therapeutic Targets. Diagnostics 2022;12:1364. [DOI: 10.3390/diagnostics12061364] [Reference Citation Analysis]
19 Canna SW, Cron RQ. Highways to hell: Mechanism-based management of cytokine storm syndromes. J Allergy Clin Immunol 2020;146:949-59. [PMID: 33007328 DOI: 10.1016/j.jaci.2020.09.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
20 Bagri NK, Gupta L, Sen ES, Ramanan AV. Macrophage Activation Syndrome in Children: Diagnosis and Management. Indian Pediatr 2021;58:1155-61. [DOI: 10.1007/s13312-021-2399-8] [Reference Citation Analysis]
21 McClain KL. Treatment of hemophagocytic lymphohistiocytosis in the era of new biologics. Pediatr Blood Cancer 2020;67:e28631. [PMID: 33030268 DOI: 10.1002/pbc.28631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 AbdelMassih AF, Ramzy D, Nathan L, Aziz S, Ashraf M, Youssef NH, Hafez N, Saeed R, Agha H. Possible molecular and paracrine involvement underlying the pathogenesis of COVID-19 cardiovascular complications. Cardiovasc Endocrinol Metab 2020;9:121-4. [PMID: 32803146 DOI: 10.1097/XCE.0000000000000207] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
23 Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST, Becker ML, Cron RQ, Feldman BM, Ferguson PJ, Gewanter H, Guzman J, Kimura Y, Lee T, Murphy K, Nigrovic PA, Ombrello MJ, Rabinovich CE, Tesher M, Twilt M, Klein-Gitelman M, Barbar-Smiley F, Cooper AM, Edelheit B, Gillispie-Taylor M, Hays K, Mannion ML, Peterson R, Flanagan E, Saad N, Sullivan N, Szymanski AM, Trachtman R, Turgunbaev M, Veiga K, Turner AS, Reston JT. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken) 2022;74:521-37. [PMID: 35233986 DOI: 10.1002/acr.24853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Cooray S, Sabanathan S, Hacohen Y, Worth A, Eleftheriou D, Hemingway C. Treatment Strategies for Central Nervous System Effects in Primary and Secondary Haemophagocytic Lymphohistiocytosis in Children. Curr Treat Options Neurol. [DOI: 10.1007/s11940-022-00705-8] [Reference Citation Analysis]
25 Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, Caricchio R, Mahmud S, Hazen MM, Halyabar O, Hoyt KJ, Han J, Grom AA, Gattorno M, Ravelli A, De Benedetti F, Behrens EM, Cron RQ, Nigrovic PA. On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis Rheumatol 2020;72:1059-63. [PMID: 32293098 DOI: 10.1002/art.41285] [Cited by in Crossref: 297] [Cited by in F6Publishing: 268] [Article Influence: 148.5] [Reference Citation Analysis]
26 Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, Behrens EM, Ferris A, Kernan KF, Schulert GS, Seo P, Son MBF, Tremoulet AH, Yeung RSM, Mudano AS, Turner AS, Karp DR, Mehta JJ. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis Rheumatol 2021;73:e13-29. [PMID: 33277976 DOI: 10.1002/art.41616] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 41.0] [Reference Citation Analysis]
27 Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, Oltolini C, Castiglioni B, Tassan Din C, Boffini N, Tomelleri A, Farina N, Ruggeri A, Rovere-Querini P, Di Lucca G, Martinenghi S, Scotti R, Tresoldi M, Ciceri F, Landoni G, Zangrillo A, Scarpellini P, Dagna L. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2:e325-e331. [PMID: 32501454 DOI: 10.1016/s2665-9913(20)30127-2] [Cited by in Crossref: 482] [Cited by in F6Publishing: 323] [Article Influence: 241.0] [Reference Citation Analysis]
28 Mendoza-Pinto C, García-Carrasco M, Munguía Realpozo P, Méndez-Martínez S. Therapeutic options for the management of severe COVID-19: A rheumatology perspective. Reumatol Clin (Engl Ed) 2021;17:431-6. [PMID: 34625144 DOI: 10.1016/j.reumae.2020.05.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2020;2:e358-e367. [PMID: 32373790 DOI: 10.1016/s2665-9913(20)30096-5] [Cited by in Crossref: 87] [Cited by in F6Publishing: 44] [Article Influence: 43.5] [Reference Citation Analysis]
30 Vagrecha A, Patel HB, Mamdouhi T, Acharya S, Appiah-Kubi A, Aygun B, Vlachos A, Wolfe LC, Lipton JM, Cron RQ, Fein Levy C. Effect of COVID-19 on anakinra-induced remission in homozygous STX11 hemophagocytosis lymphohistiocytosis. Pediatr Blood Cancer 2021;68:e28897. [PMID: 33442938 DOI: 10.1002/pbc.28897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Chou CK, Turtle CJ. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. Expert Opin Biol Ther 2020;20:653-64. [PMID: 32067497 DOI: 10.1080/14712598.2020.1729735] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
32 Fingerhutová Š, Jančová E, Doležalová P. Anakinra in Paediatric Rheumatology and Periodic Fever Clinics: Is the Higher Dose Safe? Front Pediatr 2022;10:823847. [DOI: 10.3389/fped.2022.823847] [Reference Citation Analysis]
33 Zheng X, Wu Y, Bi J, Huang Y, Cheng Y, Li Y, Wu Y, Cao G, Tian Z. The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy. Cell Mol Immunol 2022;19:192-209. [PMID: 35043005 DOI: 10.1038/s41423-021-00786-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Zhang M, Dai R, Zhao Q, Zhou L, An Y, Tang X, Zhao X. Identification of Key Biomarkers and Immune Infiltration in Systemic Juvenile Idiopathic Arthritis by Integrated Bioinformatic Analysis. Front Mol Biosci 2021;8:681526. [PMID: 34336925 DOI: 10.3389/fmolb.2021.681526] [Reference Citation Analysis]
35 Crayne C, Cron RQ. Pediatric macrophage activation syndrome, recognizing the tip of the Iceberg. Eur J Rheumatol 2019;:1-8. [PMID: 31804174 DOI: 10.5152/eurjrheum.2019.19150] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
36 Schnaubelt S, Tihanyi D, Strassl R, Schmidt R, Anders S, Laggner AN, Agis H, Domanovits H. Hemophagocytic lymphohistiocytosis in COVID-19: Case reports of a stepwise approach. Medicine (Baltimore) 2021;100:e25170. [PMID: 33761694 DOI: 10.1097/MD.0000000000025170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
37 Pontali E, Volpi S, Antonucci G, Castellaneta M, Buzzi D, Tricerri F, Angelelli A, Caorsi R, Feasi M, Calautti F, Castagnola E, Rollandi GA, Ravelli A, Cassola G, Gattorno M. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. J Allergy Clin Immunol 2020;146:213-5. [PMID: 32437739 DOI: 10.1016/j.jaci.2020.05.002] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 37.5] [Reference Citation Analysis]
38 Amigues I, Pearlman AH, Patel A, Reid P, Robinson PC, Sinha R, Kim AH, Youngstein T, Jayatilleke A, Konig M. Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. Expert Rev Clin Immunol 2020;16:1185-204. [PMID: 33146561 DOI: 10.1080/1744666X.2021.1847084] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 6.5] [Reference Citation Analysis]
39 Baldo F, Beretta G, Tibaldi J, Caorsi R, Minoia F. Macrophage Activation Syndrome in Childhood Inflammatory Disorders: Diagnosis, Genetics, Pathophysiology, and Treatment. Curr Treat Options in Rheum 2020;6:245-59. [DOI: 10.1007/s40674-020-00153-y] [Reference Citation Analysis]
40 Sandler RD, Tattersall RS, Schoemans H, Greco R, Badoglio M, Labopin M, Alexander T, Kirgizov K, Rovira M, Saif M, Saccardi R, Delgado J, Peric Z, Koenecke C, Penack O, Basak G, Snowden JA. Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Front Immunol 2020;11:524. [PMID: 32296434 DOI: 10.3389/fimmu.2020.00524] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
41 Nasonov EL. CORONAVIRUS DISEASE 2019 (COVID-19): A RHEUMATOLOGIST’S THOUGHTS. Naučno-praktičeskaâ revmatologiâ 2020;58:123-32. [DOI: 10.14412/1995-4484-2020-123-132] [Cited by in Crossref: 18] [Cited by in F6Publishing: 1] [Article Influence: 9.0] [Reference Citation Analysis]
42 Canna SW, Marsh RA. Pediatric hemophagocytic lymphohistiocytosis. Blood. 2020;135:1332-1343. [PMID: 32107531 DOI: 10.1182/blood.2019000936] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 15.5] [Reference Citation Analysis]
43 Hao Z, Li R, Meng L, Han Z, Hong Z. Macrophage, the potential key mediator in CAR-T related CRS. Exp Hematol Oncol 2020;9:15. [PMID: 32665874 DOI: 10.1186/s40164-020-00171-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
44 Kawazoe M, Kihara M, Nanki T. Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists. Pharmaceuticals (Basel) 2021;14:1256. [PMID: 34959657 DOI: 10.3390/ph14121256] [Reference Citation Analysis]
45 Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, Sacco E, Naccache JM, Bézie Y, Laplanche S, Le Berre A, Le Pavec J, Salmeron S, Emmerich J, Mourad JJ, Chatellier G, Hayem G. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol 2020;2:e393-400. [PMID: 32835245 DOI: 10.1016/S2665-9913(20)30164-8] [Cited by in Crossref: 268] [Cited by in F6Publishing: 169] [Article Influence: 134.0] [Reference Citation Analysis]
46 Mohapatra RK, Dhama K, Mishra S, Sarangi AK, Kandi V, Tiwari R, Pintilie L. The microbiota-related coinfections in COVID-19 patients: a real challenge. Beni Suef Univ J Basic Appl Sci 2021;10:47. [PMID: 34458380 DOI: 10.1186/s43088-021-00134-7] [Reference Citation Analysis]
47 Lehrer H, Scigliano E, Chan A. Central Nervous System Hemophagocytic Lymphohistiocytosis (CNS-HLH) from Leptomeningeal Anaplastic Large Cell Lymphoma : Mild Clinical Neurologic Syndrome with Extensive Multifocal White Matter Disease. Clin Neuroradiol 2021. [PMID: 33576835 DOI: 10.1007/s00062-021-00998-3] [Reference Citation Analysis]
48 Keeley AJ, Parkash V, Tunbridge A, Greig J, Collini P, McKane W, Tattersall RS. Anakinra in the treatment of protracted paradoxical inflammatory reactions in HIV-associated tuberculosis in the United Kingdom: a report of two cases. Int J STD AIDS 2020;31:808-12. [PMID: 32631210 DOI: 10.1177/0956462420915394] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
49 Stefania S, Colia R, Cinzia R, Corrado A, Cantatore FP. Off-label use of anti-IL-1 drugs in rheumatic diseases. Int J Immunopathol Pharmacol 2021;35:20587384211006584. [PMID: 33855881 DOI: 10.1177/20587384211006584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383:2255-2273. [PMID: 33264547 DOI: 10.1056/nejmra2026131] [Cited by in Crossref: 347] [Cited by in F6Publishing: 224] [Article Influence: 173.5] [Reference Citation Analysis]
51 Woolf NT. The Current Role for Biologic Medications in the Treatment of Pediatric COVID-19 and MIS-C. Pediatr Ann 2022;51. [DOI: 10.3928/19382359-20220114-01] [Reference Citation Analysis]
52 Pontali E, Volpi S, Signori A, Antonucci G, Castellaneta M, Buzzi D, Montale A, Bustaffa M, Angelelli A, Caorsi R, Giambruno E, Bobbio N, Feasi M, Gueli I, Tricerri F, Calautti F, Castagnola E, Moscatelli A, Rollandi GA, Ravelli A, Cassola G, Sormani MP, Gattorno M. Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia. J Allergy Clin Immunol 2021;147:1217-25. [PMID: 33556464 DOI: 10.1016/j.jaci.2021.01.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
53 Flower L, Laundy N, Khosravi M, Buckley J, Gale A, Kumar ID, Otenigbagbe O, Tattersall RS, Manson JJ, Quick V. Haemophagocytic lymphohistiocytosis secondary to COVID-19: a case series. Lancet Rheumatol 2021;3:e744-7. [PMID: 34423317 DOI: 10.1016/S2665-9913(21)00248-4] [Reference Citation Analysis]
54 Charlesworth JEG, Wilson S, Qureshi A, Blanco E, Mitchell A, Segal S, Kelly D, Weitz J, O'Shea D, Bailey K, Kavirayani A. Continuous intravenous anakinra for treating severe secondary haemophagocytic lymphohistiocytosis/macrophage activation syndrome in critically ill children. Pediatr Blood Cancer 2021;68:e29102. [PMID: 34114322 DOI: 10.1002/pbc.29102] [Reference Citation Analysis]
55 Zhong J, Tang J, Ye C, Dong L. The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol 2020;2:e428-36. [PMID: 32835246 DOI: 10.1016/S2665-9913(20)30120-X] [Cited by in Crossref: 108] [Cited by in F6Publishing: 66] [Article Influence: 54.0] [Reference Citation Analysis]
56 Cavalli G, Farina N, Campochiaro C, De Luca G, Della-Torre E, Tomelleri A, Dagna L. Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. Front Pharmacol 2020;11:598308. [PMID: 33442386 DOI: 10.3389/fphar.2020.598308] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
57 Bellinvia S, Edwards CJ, Schisano M, Banfi P, Fallico M, Murabito P. The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm? Inflamm Res 2020;69:757-63. [PMID: 32468151 DOI: 10.1007/s00011-020-01366-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
58 Qeadan F, Tingey B, Gu LY, Packard AH, Erdei E, Saeed AI. Prognostic Values of Serum Ferritin and D-Dimer Trajectory in Patients with COVID-19. Viruses 2021;13:419. [PMID: 33807920 DOI: 10.3390/v13030419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
59 Monteagudo LA, Boothby A, Gertner E. Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome. ACR Open Rheumatol. 2020;2:276-282. [PMID: 32267081 DOI: 10.1002/acr2.11135] [Cited by in Crossref: 89] [Cited by in F6Publishing: 74] [Article Influence: 44.5] [Reference Citation Analysis]
60 Cron RQ, Chatham WW. The Rheumatologist's Role in COVID-19. J Rheumatol 2020;47:639-42. [PMID: 32209661 DOI: 10.3899/jrheum.200334] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 29.5] [Reference Citation Analysis]
61 Poonkuzhi Naseef P, Elayadeth-Meethal M, Salim K T M, Anjana A, Muhas C, Vajid K A, Saheer Kuruniyan M. Therapeutic Potential Of Induced Iron Depletion Using Iron Chelators In Covid-19. Saudi J Biol Sci 2021. [PMID: 34924800 DOI: 10.1016/j.sjbs.2021.11.061] [Reference Citation Analysis]
62 Barkas F, Ntekouan SF, Kosmidou M, Liberopoulos E, Liontos A, Milionis H. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis. Rheumatology (Oxford) 2021:keab447. [PMID: 33999135 DOI: 10.1093/rheumatology/keab447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
63 Aswad M, Hamza H, Pechkovsky A, Zikrach A, Popov T, Zohar Y, Shahar E, Louria-Hayon I. High-CBD Extract (CBD-X) Downregulates Cytokine Storm Systemically and Locally in Inflamed Lungs. Front Immunol 2022;13:875546. [PMID: 35651623 DOI: 10.3389/fimmu.2022.875546] [Reference Citation Analysis]
64 McClain KL, Bigenwald C, Collin M, Haroche J, Marsh RA, Merad M, Picarsic J, Ribeiro KB, Allen CE. Histiocytic disorders. Nat Rev Dis Primers 2021;7:73. [PMID: 34620874 DOI: 10.1038/s41572-021-00307-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Vicenzi P, Jiwani Z, Guirola R, Hamby T, Ray A. Comment on: The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2021;68:e28813. [PMID: 33200506 DOI: 10.1002/pbc.28813] [Reference Citation Analysis]
66 Reiff DD, Stoll ML, Cron RQ. Precision medicine in juvenile idiopathic arthritis—has the time arrived? The Lancet Rheumatology 2021;3:e808-17. [DOI: 10.1016/s2665-9913(21)00252-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Yoon HS. A Recent Update on Histiocytic Disorder in Children: Focus on Diagnosis and Treatment. Clin Pediatr Hematol Oncol 2020;27:32-42. [DOI: 10.15264/cpho.2020.27.1.32] [Reference Citation Analysis]
68 Navarro-Millán I, Sattui SE, Lakhanpal A, Zisa D, Siegel CH, Crow MK. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series. Arthritis Rheumatol 2020;72:1990-7. [PMID: 32602262 DOI: 10.1002/art.41422] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 28.0] [Reference Citation Analysis]
69 Opalińska A, Kwiatkowska D, Burdacki A, Markiewicz M, Samotij D, Dudziński M, Niemiec-Dudek J, Ostańska E, Reich A. Multifocal Pyoderma Gangrenosum with an Underlying Hemophagocytic Lymphohistiocytosis: Case Report and the Review of the Literature. Dermatol Ther (Heidelb) 2021;11:1217-37. [PMID: 34176093 DOI: 10.1007/s13555-021-00571-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Li X, Shao M, Zeng X, Qian P, Huang H. Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. Signal Transduct Target Ther 2021;6:367. [PMID: 34667157 DOI: 10.1038/s41392-021-00764-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Kyriakoulis KG, Kollias A, Poulakou G, Kyriakoulis IG, Trontzas IP, Charpidou A, Syrigos K. The Effect of Anakinra in Hospitalized Patients with COVID-19: An Updated Systematic Review and Meta-Analysis. J Clin Med 2021;10:4462. [PMID: 34640480 DOI: 10.3390/jcm10194462] [Reference Citation Analysis]
72 Erkens R, Esteban Y, Towe C, Schulert G, Vastert S. Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis: Refractory Arthritis, Recurrent Macrophage Activation Syndrome and Chronic Lung Disease. Rheum Dis Clin North Am 2021;47:585-606. [PMID: 34635293 DOI: 10.1016/j.rdc.2021.06.003] [Reference Citation Analysis]
73 England JT, Abdulla A, Biggs CM, Lee AYY, Hay KA, Hoiland RL, Wellington CL, Sekhon M, Jamal S, Shojania K, Chen LYC. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. Blood Rev 2021;45:100707. [PMID: 32425294 DOI: 10.1016/j.blre.2020.100707] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 26.5] [Reference Citation Analysis]
74 Dulek DE, Fuhlbrigge RC, Tribble AC, Connelly JA, Loi MM, El Chebib H, Chandrakasan S, Otto WR, Diorio C, Keim G, Walkovich K, Jaggi P, Girotto JE, Yarbrough A, Behrens EM, Cron RQ, Bassiri H. Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients. J Pediatric Infect Dis Soc 2020;9:716-37. [PMID: 32808988 DOI: 10.1093/jpids/piaa098] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
75 Dreyzin A, Jacobsohn D, Angiolillo A, Wistinghausen B, Schore RJ, Perez E, Wells E, Terao J, Bonifant C, Rohatgi R, Dave H, Vatsayan A. Intravenous anakinra for tisagenlecleucel-related toxicities in children and young adults. Pediatr Hematol Oncol 2021;:1-9. [PMID: 34672243 DOI: 10.1080/08880018.2021.1988012] [Reference Citation Analysis]
76 Bami S, Vagrecha A, Soberman D, Badawi M, Cannone D, Lipton JM, Cron RQ, Levy CF. The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2020;67:e28581. [PMID: 32725881 DOI: 10.1002/pbc.28581] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
77 Reiff DD, Zhang M, Smitherman EA, Mannion ML, Stoll ML, Weiser P, Cron RQ. A Rare STXBP2 Mutation in Severe COVID-19 and Secondary Cytokine Storm Syndrome. Life 2022;12:149. [DOI: 10.3390/life12020149] [Reference Citation Analysis]
78 Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, Behrens EM, Ferris A, Kernan KF, Schulert GS, Seo P, F Son MB, Tremoulet AH, Yeung RSM, Mudano AS, Turner AS, Karp DR, Mehta JJ. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1. Arthritis Rheumatol 2020;72:1791-805. [PMID: 32705809 DOI: 10.1002/art.41454] [Cited by in Crossref: 101] [Cited by in F6Publishing: 81] [Article Influence: 50.5] [Reference Citation Analysis]
79 Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST, Becker ML, Cron RQ, Feldman BM, Ferguson PJ, Gewanter H, Guzman J, Kimura Y, Lee T, Murphy K, Nigrovic PA, Ombrello MJ, Rabinovich CE, Tesher M, Twilt M, Klein-Gitelman M, Barbar-Smiley F, Cooper AM, Edelheit B, Gillispie-Taylor M, Hays K, Mannion ML, Peterson R, Flanagan E, Saad N, Sullivan N, Szymanski AM, Trachtman R, Turgunbaev M, Veiga K, Turner AS, Reston JT. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol 2022;74:553-69. [PMID: 35233993 DOI: 10.1002/art.42037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
80 Pai TS, Stancampiano FF, Rivera C. Hemophagocytic Lymphohistiocytosis for the Internist and Other Primary Care Providers. J Prim Care Community Health 2021;12:21501327211053756. [PMID: 34704505 DOI: 10.1177/21501327211053756] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Phadke O, Rouster-Stevens K, Giannopoulos H, Chandrakasan S, Prahalad S. Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol Online J 2021;19:98. [PMID: 34187503 DOI: 10.1186/s12969-021-00585-3] [Reference Citation Analysis]
82 Nikiforow S, Berliner N. To "Lump" or to "Split" in Macrophage Activation Syndrome and Hemophagocytic Lymphohistiocytosis. Arthritis Rheumatol 2020;72:206-9. [PMID: 31524337 DOI: 10.1002/art.41106] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
83 Hennon TR, Yu KOA, Penque MD, Abdul-Aziz R, Chang AC, McGreevy MB, Pastore JV, Prout AJ, Schaefer BA, Alibrahim OS, Gomez-Duarte OG, Hicar MD. COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C) guidelines; revisiting the Western New York approach as the pandemic evolves. Prog Pediatr Cardiol 2021;62:101407. [PMID: 34121829 DOI: 10.1016/j.ppedcard.2021.101407] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Tran VL, Parsons S, Nuibe A. The Trilogy of SARS-CoV-2 in Pediatrics (Part 2): Multisystem Inflammatory Syndrome in Children. J Pediatr Pharmacol Ther 2021;26:318-38. [PMID: 34035676 DOI: 10.5863/1551-6776-26.4.318] [Reference Citation Analysis]
85 Cron RQ. COVID-19 cytokine storm: targeting the appropriate cytokine. Lancet Rheumatol 2021;3:e236-7. [PMID: 33655221 DOI: 10.1016/S2665-9913(21)00011-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
86 Roshanravan N, Seif F, Ostadrahimi A, Pouraghaei M, Ghaffari S. Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review. Arch Med Res 2020;51:608-12. [PMID: 32682575 DOI: 10.1016/j.arcmed.2020.06.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
87 Pan H, Wang G, Guan E, Song L, Song A, Liu X, Yi Z, Sun LR. Treatment outcomes and prognostic factors for non- malignancy associated secondary hemophagocytic lymphohistiocytosis in children. BMC Pediatr 2020;20:288. [PMID: 32517812 DOI: 10.1186/s12887-020-02178-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Worley E, Li W, Jones JT. Atypical Presentation of Systemic Arthritis in a Toddler with Down Syndrome. Case Rep Pediatr 2021;2021:6567770. [PMID: 34422425 DOI: 10.1155/2021/6567770] [Reference Citation Analysis]
89 Bray MA, Sartain SE, Gollamudi J, Rumbaut RE. Microvascular thrombosis: experimental and clinical implications. Transl Res 2020;225:105-30. [PMID: 32454092 DOI: 10.1016/j.trsl.2020.05.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
90 Nasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother 2020;131:110698. [PMID: 32920514 DOI: 10.1016/j.biopha.2020.110698] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 14.0] [Reference Citation Analysis]
91 Hakim NN, Chi J, Olazagasti C, Liu JM. Secondary hemophagocytic lymphohistiocytosis versus cytokine release syndrome in severe COVID-19 patients. Exp Biol Med (Maywood) 2021;246:5-9. [PMID: 32972235 DOI: 10.1177/1535370220962043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
92 Ajeganova S, De Becker A, Schots R. Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still's disease: when dosage matters in overcoming secondary therapy resistance. Ther Adv Musculoskelet Dis 2020;12:1759720X20974858. [PMID: 33281955 DOI: 10.1177/1759720X20974858] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
93 Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, Behrens EM, Kernan KF, Schulert GS, Seo P, Son MBF, Tremoulet AH, VanderPluym C, Yeung RSM, Mudano AS, Turner AS, Karp DR, Mehta JJ. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. Arthritis Rheumatol 2022. [PMID: 35118829 DOI: 10.1002/art.42062] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 14.0] [Reference Citation Analysis]
94 Garonzi C, Chinello M, Cesaro S. Emapalumab for adult and pediatric patients with hemophagocytic lymphohistiocytosis. Expert Rev Clin Pharmacol 2021;14:527-34. [PMID: 33686916 DOI: 10.1080/17512433.2021.1901576] [Reference Citation Analysis]
95 Kaleda MI, Nikishina IP, Fedorov ES, Nasonov EL. Coronavirus Desease 2019 (COVID-19) in Children: Lessons from Pediatric Rheumatology. Naučno-praktičeskaâ revmatologiâ 2020;58:469-79. [DOI: 10.47360/1995-4484-2020-469-479] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]